Truncated glycoprotein E of varicella-zoster virus is an ideal immunogen for Escherichia coli-based vaccine design

[1]  Cunbao Liu,et al.  LNP-CpG ODN-adjuvanted varicella-zoster virus glycoprotein E induced comparable levels of immunity with Shingrix™ in VZV-primed mice , 2022, Virologica Sinica.

[2]  Cunbao Liu,et al.  Ionizable Lipid Nanoparticles Enhanced the Synergistic Adjuvant Effect of CpG ODNs and QS21 in a Varicella Zoster Virus Glycoprotein E Subunit Vaccine , 2022, Pharmaceutics.

[3]  Cunbao Liu,et al.  Immunogenicity of Varicella-Zoster Virus Glycoprotein E Formulated with Lipid Nanoparticles and Nucleic Immunostimulators in Mice , 2021, Vaccines.

[4]  A. Ko,et al.  The Effect of a TLR4 Agonist/Cationic Liposome Adjuvant on Varicella-Zoster Virus Glycoprotein E Vaccine Efficacy: Antigen Presentation, Uptake, and Delivery to Lymph Nodes , 2021, Pharmaceutics.

[5]  Cunbao Liu,et al.  Immune Responses to Varicella-Zoster Virus Glycoprotein E Formulated with Poly(Lactic-co-Glycolic Acid) Nanoparticles and Nucleic Acid Adjuvants in Mice , 2020, Virologica Sinica.

[6]  S. Mallal,et al.  Identification and Characterization of CD4+ T Cell Epitopes after Shingrix Vaccination , 2020, Journal of Virology.

[7]  H. J. Lee,et al.  Evaluation of glycoprotein E subunit and live attenuated varicella‐zoster virus vaccines formulated with a single‐strand RNA‐based adjuvant , 2020, Immunity, inflammation and disease.

[8]  S. Tyring,et al.  Shingrix for Herpes Zoster: A Review , 2019, Skin therapy letter.

[9]  A. Ko,et al.  Efficient induction of cell-mediated immunity to varicella-zoster virus glycoprotein E co-lyophilized with a cationic liposome-based adjuvant in mice. , 2019, Vaccine.

[10]  E. Samuelsson,et al.  Recombinant Glycoprotein E of Varicella Zoster Virus Contains Glycan-Peptide Motifs That Modulate B Cell Epitopes into Discrete Immunological Signatures , 2019, International journal of molecular sciences.

[11]  Yahiya Y. Syed.  Recombinant Zoster Vaccine (Shingrix®): A Review in Herpes Zoster , 2018, Drugs & Aging.

[12]  E. Yang,et al.  Varicella-Zoster Virus Glycoproteins: Entry, Replication, and Pathogenesis , 2016, Current Clinical Microbiology Reports.

[13]  Qinjian Zhao,et al.  A highly conserved epitope-vaccine candidate against varicella-zoster virus induces neutralizing antibodies in mice. , 2016, Vaccine.

[14]  Shinn-Jang Hwang,et al.  Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. , 2015, The New England journal of medicine.

[15]  Yimin Li,et al.  A monoclonal antibody-based VZV glycoprotein E quantitative assay and its application on antigen quantitation in VZV vaccine , 2015, Applied Microbiology and Biotechnology.

[16]  Tim W. Overton,et al.  Recombinant protein production in bacterial hosts. , 2014, Drug discovery today.

[17]  Qinjian Zhao,et al.  Development of a varicella-zoster virus neutralization assay using a glycoprotein K antibody enzyme-linked immunosorbent spot assay. , 2014, Journal of virological methods.

[18]  A. Arvin,et al.  Molecular mechanisms of varicella zoster virus pathogenesis , 2014, Nature Reviews Microbiology.

[19]  Qinjian Zhao,et al.  Hepatitis E vaccine development , 2012, Human vaccines & immunotherapeutics.

[20]  N. Dendouga,et al.  Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice. , 2012, Vaccine.

[21]  Gyun Min Lee,et al.  CHO cells in biotechnology for production of recombinant proteins: current state and further potential , 2012, Applied Microbiology and Biotechnology.

[22]  S. Jacobsen,et al.  Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease. , 2011, JAMA.

[23]  Chien-Fu Hung,et al.  Cervarix™: a vaccine for the prevention of HPV 16, 18-associated cervical cancer , 2008, Biologics : targets & therapy.

[24]  P. LaRussa,et al.  The safety profile of varicella vaccine: a 10-year review. , 2008, The Journal of infectious diseases.

[25]  S. Singh,et al.  Solubilization and refolding of bacterial inclusion body proteins. , 2005, Journal of bioscience and bioengineering.

[26]  R. Whitley,et al.  Clinical practice. Herpes zoster. , 2002, The New England journal of medicine.

[27]  K. Soike,et al.  Expression of the simian varicella virus glycoprotein E. , 2001, Virus research.

[28]  J. Adkins,et al.  Recombinant Hepatitis B Vaccine , 1998, BioDrugs.

[29]  D. Jeffries,et al.  Identification of immunodominant regions and linear B cell epitopes of the gE envelope protein of varicella-zoster virus. , 1995, Virology.

[30]  A. Arvin.  Cell-mediated immunity to varicella-zoster virus. , 1992, The Journal of infectious diseases.

[31]  Y. Okuno,et al.  Live vaccine used to prevent the spread of varicella in children in hospital. , 1974, Lancet.

[32]  L. Firman-Edwards.  Varicella , 1955 .

[33]  J. Adkins,et al.  Recombinant hepatitis B vaccine: a review of its immunogenicity and protective efficacy against hepatitis B. , 1998, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy.

[34]  A. Vafai.  Antibody-binding sites on truncated forms of varicella-zoster virus gpI(gE) glycoprotein. , 1994, Vaccine.